Tag

Alk Mutation

All articles tagged with #alk mutation

Pfizer's Lung Cancer Drug Projected to Surpass $1 Billion in Sales

Originally Published 1 year ago — by Fox Business

Pfizer anticipates its lung cancer drug Lorbrena will surpass $1 billion in annual sales by 2030, driven by strong five-year clinical trial data showing significant disease progression-free survival rates in patients with ALK-positive advanced lung cancer. The drug, which outperforms Pfizer's earlier treatment Xalkori, has shown particularly promising results in patients with brain metastases and is expected to see substantial market growth, especially in China.

business businesshealth alk-mutation businesshealth lorbrena lung-cancer pfizer sales-forecast

Pfizer's Lorbrena Shows Breakthrough Results in Advanced Lung Cancer Trials

Originally Published 1 year ago — by NBC News

Pfizer's drug Lorbrena significantly extends the life expectancy of patients with ALK-positive non-small cell lung cancer, a rare and particularly deadly form of the disease. New research shows that 60% of patients treated with Lorbrena were still alive after five years, compared to 8% of those treated with crizotinib. Lorbrena also effectively prevents brain metastasis, a common and severe complication of ALK-positive lung cancer. However, the drug may cause more neurotoxic side effects, which can be managed by adjusting the dosage.

business health alk-mutation clinical-trial health lorbrena lung-cancer pfizer